8 10, 2021

Qkine appoints Japanese distribution partner MBL to extend global availability of its innovative stem cell and organoid culture reagents

2021-10-08T12:15:37+00:00October 8th, 2021|animal-free, News, organoid news|

Qkine has concluded a sales distribution agreement with Japanese company, MBL Medical & Biological Laboratories Co., Ltd. MBL have extensive knowledge and presence within the Japanese regenerative medicine and iPSC sector, an important market for Qkine's high purity, animal-free optimised growth factor and cytokine proteins. The two companies share a focus on product quality and the emerging areas of organoid and organ-on-chip technologies for basic research, personalised medicine and drug discovery. This distributor agreement between Qkine and MBL will facilitate access to Qkine's entire range of premium quality, animal-free and novel optimised growth factor proteins across Japan.

26 07, 2021

Qkine and Enantis sign licensing deal for hyperstable FGF2-STAB®

2021-07-26T08:14:57+00:00July 26th, 2021|animal-free, cellular agriculture, News, Press Release, protein engineering, protein science, stem cells|

Qkine and Enantis have concluded a global licensing deal for Enantis’s patented FGF2-STAB® technology. FGF2-STAB® is a hyperstable form of FGF-2 (bFGF), a core reagent for stem cell culture. FGF2-STAB (FGF2-G3) does not degrade in culture media for enhanced weekend-free stem cell culture media and advanced chemically defined systems, such as those needed in the cultured meat industry.

25 11, 2020

Qkine, with UK biotechnology companies Manchester BIOGEL and Cellesce, is developing fully synthetic animal-free scaffolds to overcome barriers in sustainable and scalable organoid culture, in a project funded by Innovate UK

2022-02-07T13:30:35+00:00November 25th, 2020|animal-free, News, organoid news|

Qkine, Manchester BIOGEL and Cellesce have been awarded Innovate UK Sustainable Innovation Funding to develop fully synthetic, chemically-defined three-dimensional (3D) scaffolds to enable manufacture scale up and improve reproducibility of patient-derived organoids.

26 08, 2020

Implementing animal-free recombinant proteins into stem cell supply chains

2022-02-07T13:06:59+00:00August 26th, 2020|animal-free, protein engineering, quality, stem cells|

Implementing animal-free recombinant proteins into stem cell supply chains Most industries today are under pressure to switch to more ethical and sustainable animal-free alternatives, and now the trend is coming to stem cell labs. As stem cell applications accelerate towards the clinic, novel drug discovery platforms are rapidly scaled, and [...]


Go to Top